Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pharmacotherapy

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.25.2.157.56950PMID 15767231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.

  2004cited by this paper
• Heparin-induced thrombocytopenia and cardiac surgery.

  2003cited by this paper
• Antithrombotic therapy for venous thromboembolic disease.

  2001cited by this paper
• Managing oral anticoagulant therapy.

  2001cited by this paper
• Interpreting the International Normalized Ratio (INR) in Individuals Receiving Argatroban and Warfarin

  2001cited by this paper
• Recombinant Hirudin in Clinical Practice: Focus on Lepirudin

  2001cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• The clinical management of heparin-induced thrombocytopenia.

  1999cited by this paper
• Coagulation laboratory testing in patients treated with argatroban.

  1999cited by this paper
• Antigens involved in heparin-induced thrombocytopenia.

  1999cited by this paper
• Prolonged heparin administration during clopidogrel treatment in healthy subjects.

  1999cited by this paper
• Preservation of the Chief Medical Residency

  1998cited by this paper
• Monitoring warfarin therapy in patients with lupus anticoagulants.

  1997cited by this paper
• Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management.

  1997cited by this paper
• Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs.

  1997cited by this paper
• A 14-year study of heparin-induced thrombocytopenia.

  1996cited by this paper
• Antithrombotic therapy for venous thromboembolic disease.

  1995cited by this paper
• Antithrombotic therapy for venous thromboembolic disease.

  1992cited by this paper
• Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants.

  1980cited by this paper

• Chromogenic Factor X Assay for Monitoring Warfarin Anticoagulation in a Child With a Prosthetic Mitral Valve

  2021cites this paper
• Snake Venoms in Diagnostic Hemostasis and Thrombosis

  2021cites this paper
• Single‐center determination of reference factor II and factor X activity level values for the monitoring of vitamin K antagonist therapy

  2019cites this paper
• Transitioning Between Anticoagulants

  2018cites this paper
• Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors

  2017cites this paper
• Utilization Management Employing Test Interpretations and Algorithms

  2017cites this paper
• Minimal Prolongation of Prothrombin Time with Extended Exposure to Argatroban

  2015cites this paper
• Non–injection‐site necrotic skin lesions complicating postoperative heparin thromboprophylaxis

  2015cites this paper
• Evaluation of 2 Nomogram-Based Strategies for Dosing Argatroban in Patients With Known or Suspected Heparin-Induced Thrombocytopenia

  2015cites this paper
• Laboratory test interpretations and algorithms in utilization management.

  2014cites this paper
• Intravenous Warfarin and Heparin-Induced Thrombocytopenia

  2014cites this paper
• WITHDRAWN: Laboratory Test Interpretations and Algorithms in Utilization Management

  2013cites this paper
• Diagnosis and management of heparin-induced thrombocytopenia.

  2013cites this paper
• Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients.

  2013cites this paper
• Pathology consultation on anticoagulation monitoring: factor X-related assays.

  2013cites this paper
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Use of the Chromogenic Factor X Assay in Patients Transitioning from Argatroban to Warfarin Therapy

  2012influential citation
• The identification and management of heparin-induced thrombocytopenia in the vascular patient.

  2012cites this paper
• Bleeding risks and response to therapy in patients with INR higher than 9.

  2012cites this paper
• Test of the month: The chromogenic antifactor Xa assay

  2012cites this paper
• Monitoring of direct anticoagulants

  2011cites this paper
• Venous thromboembolic disease.

  2011cites this paper
• Venous Thromboembolic DiseasePractice Guidelines in Oncology

  2011cites this paper
• Laboratory monitoring of new anticoagulants

  2010cites this paper
• Reducing Harm Associated with Anticoagulation

  2009cites this paper
• Reducing Harm Associated with Anticoagulation Considerations of Argatroban Therapy in

  2009cites this paper
• INR matters: a case on managing argatroban for bridging oral anticoagulation in a patient with heparin induced thrombocytopenia type II after mechanical heart valve replacement.

  2009cites this paper
• Heparin induced thrombocytopenia and re‐thrombosis associated with warfarin and fondaparinux in a child

  2009cites this paper
• Argatroban therapy in heparin-induced thrombocytopenia

  2008cites this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy

  2008cites this paper
• Argatroban therapy in

  2008cites this paper
• Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College

  2008cites this paper
• Heparin-Induced Thrombocytopenia

  2008cites this paper
• Dysfunction Thrombocytopenia With Hepatic Argatroban Therapy in Heparin-Induced

  2007cites this paper
• Heparin‐Induced Thrombocytopenia: Treatment Options and Special Considerations

  2007cites this paper
• Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia

  2007cites this paper
• Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients

  2007cites this paper
• Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

  2007cites this paper
• Heparin-induced thrombocytopenia, a prothrombotic disease.

  2007cites this paper
• Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.

  2006cites this paper
• Venous thromboembolic disease. Clinical practice guidelines in oncology.

  2006cites this paper